Gastrin-releasing peptide receptor imaging in human breast carcinoma versus immunohistochemistry

被引:79
作者
de Wiele, Christophe Van [1 ,2 ]
Phonteyne, Philippe [1 ,2 ]
Pauwels, Patrick [3 ]
Goethals, Ingeborg [1 ]
Van den Broecke, Rudi [4 ]
Cocquyt, Veronique [5 ]
Dierckx, Rudi Andre [1 ,2 ]
机构
[1] Ghent Univ Hosp, Dept Nucl Med, B-9000 Ghent, Belgium
[2] Univ Groningen, Univ Med Ctr Groningen, Dept Nucl Med & Mol Imaging, Groningen, Netherlands
[3] Ghent Univ Hosp, Dept Anatomopathol, B-9000 Ghent, Belgium
[4] Ghent Univ Hosp, Div Gynaecol Oncol, B-9000 Ghent, Belgium
[5] Ghent Univ Hosp, Dept Med Oncol, B-9000 Ghent, Belgium
关键词
D O I
10.2967/jnumed.107.047167
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
This study reports on the uptake of Tc-99m-RP527 by human breast carcinoma and its relationship to gastrin-releasing peptide receptor (GRIP-R) expression as measured by immunohistochemistry (IHC). Methods: Nine patients referred because of a clinical diagnosis suggestive of breast carcinoma and 5 patients with tamoxifen-resistant be-m breast carcinoma underwent 99mTc-RP527 scintigraphy. The findings were compared with routine staging examinations in all patients and with routine histology and IHC GRP-R staining in the first 9 patients. All 9 patients with suspected breast lesions were tumor positive. Results: The uptake of Tc-99m-RP527 was evident in the primary tumor in 8 of 9 patients and in involved lymph nodes and part of the distant metastasis limited to the bone when present. Tc-99m-RP527 uptake was not found in any of the tamoxifen-resistant patients. Conclusion: Uptake by primary breast carcinoma was significantly correlated with the presence of GRP-Rs as assessed by means of IHC.
引用
收藏
页码:260 / 264
页数:5
相关论文
共 14 条
[1]   Targeted therapy of breast and gynecological cancers with cytotoxic analogues of peptide hormones [J].
Engel, Joerg B. ;
Schallly, Andrew V. ;
Dietl, Johannes ;
Rieger, Lorenz ;
Hoenig, Arnd .
MOLECULAR PHARMACEUTICS, 2007, 4 (05) :652-658
[2]   Gastrin-releasing peptide receptors in non-neoplastic and neoplastic human breast [J].
Gugger, M ;
Reubi, JC .
AMERICAN JOURNAL OF PATHOLOGY, 1999, 155 (06) :2067-2076
[3]  
HALMOS G, 1995, CANCER RES, V55, P280
[4]  
HOFMANN TJ, 1999, J NUCL MED S, V40
[5]   The case for gastrin-releasing peptide acting as a morphogen when it and its receptor are aberrantly expressed in cancer [J].
Jensen, JAG ;
Carroll, RE ;
Benya, RV .
PEPTIDES, 2001, 22 (04) :689-699
[6]  
LOOSE D, 2007, EUR J NUCL MED 1010
[7]   Targeting cytotoxic conjugates of somatostatin, luteinizing hormone-releasing hormone and bombesin to cancers expressing their receptors: A "smarter" chemotherapy [J].
Nagy, A ;
Schally, AV .
CURRENT PHARMACEUTICAL DESIGN, 2005, 11 (09) :1167-1180
[8]  
Panigone S, 2006, Q J NUCL MED MOL IM, V50, P310
[9]   Technetium-99m RP527, a GRP analogue for visualisation of GRP receptor-expressing malignancies: a feasibility study [J].
Van de Wiele, C ;
Dumont, F ;
Vanden Broecke, R ;
Oosterlinck, W ;
Cocquyt, V ;
Serreyn, R ;
Peers, S ;
Thornback, J ;
Slegers, G ;
Dierckx, RA .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 2000, 27 (11) :1694-1699
[10]   Is there a role for agonist gastrin-releasing peptide receptor radioligands in tumour imaging? [J].
Van de Wiele, C ;
Dumont, F ;
Van Belle, S ;
Slegers, G ;
Peers, SH ;
Dierckx, RA .
NUCLEAR MEDICINE COMMUNICATIONS, 2001, 22 (01) :5-15